Cytokeratin 7-negative and GATA binding protein 3-negative breast cancers: Clinicopathological features and prognostic significance

• Published in: BMC cancer Vol. 19; no. 1; p. 1085
• Main Authors: Lu, Shaolei, Yakirevich, Evgeny, Wang, Li Juan, Resnick, Murray B, Wang, Yihong
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 12.11.2019; BioMed Central; BMC
• Subjects: Aged; Biomarkers, Tumor; Breast cancer; Breast carcinoma; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Breast tumors; Carcinoma; CK7; Criminal investigation; Estrogens; Female; GATA3; GATA3 Transcription Factor - genetics; GATA3 Transcription Factor - metabolism; Genetic aspects; Hormones; Humans; Immunohistochemistry; Keratin; Keratin-7 - genetics; Keratin-7 - metabolism; Middle Aged; Neoplasm Grading; Neoplasm Staging; Phenols (Class of compounds); Progesterone; Prognosis; Proportional Hazards Models; Protein binding; Sex hormones; Tumors; United Kingdom; Immunohistochemistry; Breast carcinoma; GATA3; CK7
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-019-6295-8

Cytokeratin 7 (CK7) and GATA binding protein 3 (GATA3) are considered as immunohistochemical hallmarks of breast cancers; however, there are breast tumors lacking these markers. Clinicopathological characterization of CK7 negative breast cancer has not been addressed previously and similar studies on GATA3 negative tumors are limited. This study included 196 consecutive cases of Nottingham Grade 3 breast cancers with 159 cases of Grade 1 and Grade 2 tumors for comparison. CK7 and GATA3 expression was correlated with patient's age, histological type, pathological grade and stage, hormone receptor status, molecular subtype and overall survival. CK7 negativity was seen in 13% of Grade 3, 9% of Grade 2, and 2% of Grade 1 cases (P = 0.0457). Similarly, 28% of Grade 3, 5% of Grade 2 and 2% of Grade 1 cases were GATA3 negative (P < 0.0001). CK7 negative tumors did not show association with other clinicopathological parameters. GATA3 negative tumors were enriched in the basal-like molecular subgroup and were associated with negative estrogen receptor (ER) and negative progesterone receptor (PR) statuses. Both CK7 and GATA3 expression showed no association with overall survival in patients with Grade 3 tumor. This is the first study to characterize CK7 negative breast tumors in the context of clinicopathology. Profiling the CK7 negative and GATA3 negative breast cancers helps to understand the biology of these specific tumor subgroups and may aid in their diagnosis.